Main Article Content
This article analyzes the effectiveness of Liraglutide and its impact on cardiometabolic risk factors in patients with obesity. The effectiveness of Victoza (liraglutide 3.0 mg) was studied in relation to changes in the mass index, body mass, body mass (BM), waist circumference (WC), blood pressure parameters and its effect on cardiometabolic factors. Сomplex therapy with the use of Liraglutide per day for 3 months is effective for the therapy of obesity and correction of obesity-associated cardiometabolic disturbances.
Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. // РМЖ, 2001, № 2(9). С. 56-60.
Astrup Al, Саггаго R, Finer N, et аll. Safety, tolerability and sustained weight loss over 2 years with the oncedaily human GLP-1 analog, liraglutide. // Int.J.Ohes (Lond), 2013. № 37(2). Р. 322.
Dombrowski S.U. Knittle K, et al. Long term maintenance of weight loss with nonsurgical interventions in obese adults: systerhal; review and meta-analyses of randomised controlled trials // BMJ, 2014. № 348. Р. 2646.
Jensen M.D., Ryan M.D., Donato S.M. et al. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Published by The Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines.// Based on a systematic review from the Obesity Expert Panel, 2013. Obesity (Silver Spring), 2014. № 22 (suppl 2). Р. 5-39.
Wadden T.A., Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study// Int. J. Obes. (Lond), 2013. № 37(11). Р. 1514.
World Health Organization. Obesity: preventing and managing the-global epidemic. Geneva, Switzerland: World Health Organization, 1998.